Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish
- PMID: 30572006
- PMCID: PMC6436385
- DOI: 10.1016/j.jhep.2018.11.034
Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish
Abstract
Background & aims: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) is an increasing clinical problem associated with progression to hepatocellular carcinoma (HCC). The effect of a high-fat diet on the early immune response in HCC is poorly understood, while the role of metformin in treating NAFLD and HCC remains controversial. Herein, we visualized the early immune responses in the liver and the effect of metformin on progression of HCC using optically transparent zebrafish.
Methods: We used live imaging to visualize liver inflammation and disease progression in a NAFLD/NASH-HCC zebrafish model. We combined a high-fat diet with a transgenic zebrafish HCC model induced by hepatocyte-specific activated beta-catenin and assessed liver size, angiogenesis, micronuclei formation and inflammation in the liver. In addition, we probed the effects of metformin on immune cell composition and early HCC progression.
Results: We found that a high-fat diet induced an increase in liver size, enhanced angiogenesis, micronuclei formation and neutrophil infiltration in the liver. Although macrophage number was not affected by diet, a high-fat diet induced changes in macrophage morphology and polarization with an increase in liver associated TNFα-positive macrophages. Treatment with metformin altered macrophage polarization, reduced liver size and reduced micronuclei formation in NAFLD/NASH-associated HCC larvae. Moreover, a high-fat diet reduced T cell density in the liver, which was reversed by treatment with metformin.
Conclusions: These findings suggest that diet alters macrophage polarization and exacerbates the liver inflammatory microenvironment and cancer progression in a zebrafish model of NAFLD/NASH-associated HCC. Metformin specifically affects the progression induced by diet and modulates the immune response by affecting macrophage polarization and T cell infiltration, suggesting possible effects of metformin on tumor surveillance.
Lay summary: This paper reports a new zebrafish model that can be used to study the effects of diet on liver cancer. We found that a high-fat diet promotes non-resolving inflammation in the liver and enhances cancer progression. In addition, we found that metformin, a drug used to treat diabetes, inhibits high-fat diet-induced cancer progression in this model, by reducing diet-induced non-resolving inflammation and potentially restoring tumor surveillance.
Keywords: High-fat diet; Liver cancer; Metformin; NAFLD-associated HCC; NAFLD/NASH; Zebrafish model.
Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Figures








Similar articles
-
Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.J Vis Exp. 2021 Apr 1;(170). doi: 10.3791/62457. J Vis Exp. 2021. PMID: 33871465
-
Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.J Hepatol. 2021 Mar;74(3):511-521. doi: 10.1016/j.jhep.2020.09.033. Epub 2020 Oct 8. J Hepatol. 2021. PMID: 33038434
-
Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.J Transl Med. 2015 Jun 16;13:193. doi: 10.1186/s12967-015-0552-7. J Transl Med. 2015. PMID: 26077675 Free PMC article.
-
Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.Int J Mol Sci. 2021 May 9;22(9):5016. doi: 10.3390/ijms22095016. Int J Mol Sci. 2021. PMID: 34065108 Free PMC article. Review.
-
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17. Indian J Med Res. 2019. PMID: 31115369 Free PMC article. Review.
Cited by
-
Mitochondrial Inhibition: a Treatment Strategy in Cancer?Curr Oncol Rep. 2021 Mar 17;23(4):49. doi: 10.1007/s11912-021-01033-x. Curr Oncol Rep. 2021. PMID: 33730242 Review.
-
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.Front Pharmacol. 2024 Jan 19;14:1336216. doi: 10.3389/fphar.2023.1336216. eCollection 2023. Front Pharmacol. 2024. PMID: 38313077 Free PMC article. Review.
-
A new insight: crosstalk between neutrophil extracellular traps and the gut-liver axis for nonalcoholic fatty liver disease.Front Immunol. 2025 Jun 27;16:1599956. doi: 10.3389/fimmu.2025.1599956. eCollection 2025. Front Immunol. 2025. PMID: 40655142 Free PMC article. Review.
-
Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer.Am J Cancer Res. 2020 Sep 1;10(9):2851-2864. eCollection 2020. Am J Cancer Res. 2020. PMID: 33042621 Free PMC article.
-
Senescence-Independent Anti-Inflammatory Activity of the Senolytic Drugs Dasatinib, Navitoclax, and Venetoclax in Zebrafish Models of Chronic Inflammation.Int J Mol Sci. 2022 Sep 9;23(18):10468. doi: 10.3390/ijms231810468. Int J Mol Sci. 2022. PMID: 36142384 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases